CompletedPhase 2NCT00390858

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Studying Thalassemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novartis Pharmaceuticals
Principal Investigator
Dr. Gianluca Forni
Novartis Pharmaceuticals
Intervention
Deferasirox(drug)
Enrollment
40 enrolled
Eligibility
1-18 years · All sexes
Timeline
2003 – 2008

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00390858 on ClinicalTrials.gov

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

See all trials for Thalassemia →

← Back to all trials